Precision BioSciences (DTIL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 20, 2026.
Voting matters and shareholder proposals
Election of two Class I directors: Melinda Brown and Geno Germano.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Advisory approval of executive compensation (say-on-pay vote).
Approval of amendment and restatement of the 2019 Incentive Award Plan.
Amendment to Certificate of Incorporation for officer exculpation under Delaware law.
Approval to adjourn the meeting if additional proxy solicitation is needed.
Board of directors and corporate governance
Board recommends voting in favor of all proposals and director nominees.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Precision BioSciences
- First clinical proof of cccDNA elimination achieved; cash runway supports milestones through 2028.DTIL
Q2 2026 - New gene editing platforms show strong clinical promise and expanding commercial potential.DTIL
Chardan’s 9th Annual Genetic Medicines Conference - Advancing gene editing programs show early efficacy and safety, backed by a strong cash position.DTIL
Sidoti May Micro-Cap Virtual Conference - PBGENE-HBV achieves direct cccDNA elimination in HBV, with durable biomarker response and strong clinical momentum.DTIL
Jefferies Global Healthcare Conference 2026 - PBGENE-HBV achieved complete pgRNA loss and durable cccDNA elimination in all treated patients.DTIL
Study update - All proposals were approved, with strong progress in clinical programs and financial stability.DTIL
AGM 2026 - Q1 2026 revenue reached $10.8M, net loss narrowed, and cash runway extends through 2028.DTIL
Q1 2026 - Lead gene editing programs show promising early results, with major data expected in 2026.DTIL
25th Annual Needham Virtual Healthcare Conference - PBGENE-DMD advances toward 2026 clinical trials, showing durable efficacy and safety in DMD models.DTIL
Status Update